Cutaneous gamma/delta T-cell lymphoma.
Only 40 cases of primary cutaneous gamma/delta T-cell lymphoma (GD-TCL) have been described. GD-TCL was included as a provisional entity in the WHO-EORTC classification of cutaneous lymphomas in 2005. GD-TCL often failed to respond to polychemotherapy and radiation therapy and have a poor prognosis with a mean survival of only 15 months. We present a patient treated with surgery, immunomodulatory therapy, and polychemotherapy. He then received hematopoietic stem cell transplantation and has been in complete remission since. Allogeneic stem cell transplantation appears to be a promising therapeutic option for aggressive and generally fatal lymphomas like GD-TCL.
Koch
Richard
R
Eduard-Arning Clinic for Dermatology and Allergology Asklepios Klinik St. Georg, Lohmühlenstraße 5, Hamburg, Germany. ri.koch@asklepios.com
Jaffe
Elaine S
ES
Mensing
Christian
C
Zeis
Matthias
M
Schmitz
Norbert
N
Sander
Christian A
CA
D000328:Adult; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000235:genetics / Q000473:pathology* / Q000601:surgery*; D008297:Male; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000235:genetics; D012878:Skin Neoplasms / Q000235:genetics / Q000473:pathology* / Q000601:surgery*; D033581:Stem Cell Transplantation; D016896:Treatment Outcome
D016692:Receptors, Antigen, T-Cell, gamma-delta
J Am Acad Dermatol. 2007 Apr;56(4):643-7
17367613
Bone Marrow Transplant. 2008 Apr;41(7):597-604
18176611
Blood. 2005 May 15;105(10):3768-85
15692063
Arch Dermatol. 2000 Aug;136(8):1024-32
10926739
Int J Hematol. 1999 Apr;69(3):186-95
10222658